Drug Approval | June 12, 2023
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Construction will begin this year with the new capacity anticipated by 2025
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The new recycling facility, Recover Louth, is the second addition to Coveris’ closed loop recycling business segment
Subscribe To Our Newsletter & Stay Updated
